Damora Therapeutics Inc.
Organization details
- Legal name
- Damora Therapeutics Inc.
- Former names
- Galecto, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- Denmark
- Fiscal year end
- December
- Ticker symbol
- DMRA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001800315
- EIN
- 37-1957007
Board of directors
-
Amit Munshi · DirectorSince 2023
-
Amy B. Wechsler · DirectorSince 2024
-
Andrew Cheng · DirectorSince 2026
-
Anne Prener · DirectorSince 2023
-
Cameron Turtle · DirectorSince 2026
-
Carl Goldfischer · DirectorSince 2023
-
Chau Quang Khuong · DirectorSince 2023
-
Christopher W. Cain · DirectorSince 2025
-
David Shapiro · DirectorSince 2023
-
Hans T. Schambye · Director · Chief Executive OfficerSince 2023
-
Jayson Donald Alexander Dallas · DirectorSince 2023
- Since 2026
-
Julianne Bruno · DirectorSince 2025
-
Michael Landsittel · DirectorSince 2026
- Since 2025
Chief executives
Director election results
Annual meeting of April 28, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
99.9%
Board connections
10 of this board's directors also sit on 21 other boards. 20 are in the same sector.
-
Cogent Biosciences Inc. Same sectorvia Christopher W. Cain and Peter Evan Harwin
-
Jade Biosciences Inc. Same sectorvia Christopher W. Cain and Peter Evan Harwin
-
Oruka Therapeutics Inc. Same sectorvia Cameron Turtle and Peter Evan Harwin
-
Spyre Therapeutics Inc. Same sectorvia Cameron Turtle and Peter Evan Harwin
-
Viridian Therapeutics Inc. Same sectorvia Christopher W. Cain and Peter Evan Harwin
-
Zura Bio Limited Same sectorvia Amit Munshi and Jennifer Jarrett
-
Arcus Biosciences Inc. Same sectorvia Jennifer Jarrett
-
Arcutis Biotherapeutics Inc. Same sectorvia Amit Munshi
-
Bausch Health Companies Inc. Same sectorvia Amy B. Wechsler
-
Crescent Biopharma Inc. Same sectorvia Peter Evan Harwin
-
Design Therapeutics Inc. Same sectorvia David Shapiro
-
Dianthus Therapeutics Inc. Same sectorvia Peter Evan Harwin
-
Inhibikase Therapeutics Inc. Same sectorvia Amit Munshi
-
Keros Therapeutics Inc. Same sectorvia Anne Prener
-
Korsana Biosciences Inc. Same sectorvia Peter Evan Harwin
-
NextCure Inc. Same sectorvia Chau Quang Khuong
-
Sagimet Biosciences Inc. Same sectorvia Jennifer Jarrett
-
Syndax Pharmaceuticals Inc. Same sectorvia Jennifer Jarrett
- via Andrew Cheng
-
Vera Therapeutics Inc. Same sectorvia Andrew Cheng
-
Zenas BioPharma Inc. Same sectorvia Peter Evan Harwin
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $252,875
- 1 purchase by 1 insider
- Sold, last 12 months
- $30,653
- 4 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 25, 2026 | Jennifer Jarrett Director, Officer (Director, President and CEO) | Open-market purchase | +12,500 | $20.23 | $252,875 |
| Jul 6, 2026 | Winslow Garrett Officer (General Counsel) | Open-market sale | −245 | $29.98 | $7,345 |
| Jul 3, 2026 | Winslow Garrett Officer (General Counsel) | Option exercise | +680 | — | — |
| Mar 30, 2026 | Jennifer Jarrett Director, Officer (See Remarks) | Grant or award | +500,000 | — | — |
| Feb 9, 2026 | Julianne Bruno Director | Option exercise | +129,000 | — | — |
| Feb 9, 2026 | Peter Evan Harwin Director, 10% owner | Option exercise | +5,809,000 | — | — |
| Feb 9, 2026 | Peter Evan Harwin Director, 10% owner | Option exercise | +2,904,000 | — | — |
| Jan 5, 2026 | Sattarzadeh Sherwin Officer (Chief Operating Officer) | Grant or award | +190,376 | — | — |
| Jan 5, 2026 | Hewes L. Becker Officer (Chief Medical Officer) | Grant or award | +264,629 | — | — |
| Jan 2, 2026 | Hans T. Schambye Director, Officer (Chief Executive Officer) | Option exercise | +1,360 | — | — |
| Jan 2, 2026 | Winslow Garrett Officer (General Counsel) | Option exercise | +680 | — | — |
| Jan 2, 2026 | Firmani Lori Officer (Chief Financial Officer) | Option exercise | +374 | — | — |
| Jan 2, 2026 | Hans T. Schambye Director, Officer (Chief Executive Officer) | Open-market sale | −700 | $21.38 | $14,966 |
| Jan 2, 2026 | Winslow Garrett Officer (General Counsel) | Open-market sale | −255 | $21.38 | $5,452 |
| Jan 2, 2026 | Firmani Lori Officer (Chief Financial Officer) | Open-market sale | −135 | $21.41 | $2,890 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Damora Therapeutics Inc.
Who is the CEO of Damora Therapeutics Inc.?
Hans T. Schambye is Damora Therapeutics Inc.'s Chief Executive Officer.
How many directors are on Damora Therapeutics Inc.'s board?
Damora Therapeutics Inc.'s board has 15 directors: Amit Munshi, Amy B. Wechsler, Andrew Cheng, Anne Prener, Cameron Turtle, Carl Goldfischer, Chau Quang Khuong, Christopher W. Cain, David Shapiro, Hans T. Schambye and 5 others.
Are Damora Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Damora Therapeutics Inc. insiders bought $252,875 of shares in 1 purchase and sold $30,653 of shares in 4 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="damora-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.